Literature DB >> 17045205

Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner.

Jennifer E Skeen1, Prashanth T Bhaskar, Chia-Chen Chen, William S Chen, Xiao-ding Peng, Veronique Nogueira, Annett Hahn-Windgassen, Hiroaki Kiyokawa, Nissim Hay.   

Abstract

Akt contributes to tumorigenesis by inhibiting apoptosis. Here we establish that Akt is required for normal cell proliferation and susceptibility to oncogenesis independently of its antiapoptotic activity. Partial ablation of Akt activity by deleting Akt1 inhibits cell proliferation and oncogenesis. These effects are compounded by deleting both Akt1 and Akt2. In vivo, Akt1 null mice are resistant to MMTV-v-H-Ras-induced tumors and to skin carcinogenesis. Thus, partial ablation of Akt activity is sufficient to suppress tumorigenesis in vitro and in vivo. The effect of Akt deficiency on cell proliferation and oncogenesis is p53 independent but mTORC1 dependent. Surprisingly, upon mTORC1 hyperactivation, the reduction in Akt activity does not impair cell proliferation and susceptibility to oncogenic transformation; thus, Akt may mediate these processes exclusively via mTORC1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17045205     DOI: 10.1016/j.ccr.2006.08.022

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  109 in total

1.  AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress.

Authors:  Sang-Min Jeon; Navdeep S Chandel; Nissim Hay
Journal:  Nature       Date:  2012-05-09       Impact factor: 49.962

Review 2.  Mitochondrial regulation of cell cycle and proliferation.

Authors:  Valeria Gabriela Antico Arciuch; María Eugenia Elguero; Juan José Poderoso; María Cecilia Carreras
Journal:  Antioxid Redox Signal       Date:  2012-01-13       Impact factor: 8.401

3.  Mnk earmarks eIF4E for cancer therapy.

Authors:  Nissim Hay
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

4.  Akt-dependent Skp2 mRNA translation is required for exiting contact inhibition, oncogenesis, and adipogenesis.

Authors:  Veronique Nogueira; Deepa Sundararajan; Jennifer M Kwan; Xiao-ding Peng; Neha Sarvepalli; Nahum Sonenberg; Nissim Hay
Journal:  EMBO J       Date:  2012-02-03       Impact factor: 11.598

5.  Akt isoforms differentially regulate neutrophil functions.

Authors:  Jia Chen; Haiyang Tang; Nissim Hay; Jingsong Xu; Richard D Ye
Journal:  Blood       Date:  2010-03-23       Impact factor: 22.113

6.  DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.

Authors:  Timothy R Peterson; Mathieu Laplante; Carson C Thoreen; Yasemin Sancak; Seong A Kang; W Michael Kuehl; Nathanael S Gray; David M Sabatini
Journal:  Cell       Date:  2009-05-14       Impact factor: 41.582

7.  FAK Promotes Early Osteoprogenitor Cell Proliferation by Enhancing mTORC1 Signaling.

Authors:  Shuqun Qi; Xiumei Sun; Han Kyoung Choi; Jinfeng Yao; Li Wang; Guomin Wu; Yun He; Jian Pan; Jun-Lin Guan; Fei Liu
Journal:  J Bone Miner Res       Date:  2020-06-05       Impact factor: 6.741

8.  Glucocorticoid receptor β stimulates Akt1 growth pathway by attenuation of PTEN.

Authors:  Lance A Stechschulte; Leah Wuescher; Joseph S Marino; Jennifer W Hill; Charis Eng; Terry D Hinds
Journal:  J Biol Chem       Date:  2014-05-09       Impact factor: 5.157

9.  mTORC1 promotes survival through translational control of Mcl-1.

Authors:  John R Mills; Yoshitaka Hippo; Francis Robert; Samuel M H Chen; Abba Malina; Chen-Ju Lin; Ulrike Trojahn; Hans-Guido Wendel; Al Charest; Roderick T Bronson; Scott C Kogan; Robert Nadon; David E Housman; Scott W Lowe; Jerry Pelletier
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-29       Impact factor: 11.205

10.  Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.

Authors:  Jingxiang Huang; Shulin Wu; Chin-Lee Wu; Brendan D Manning
Journal:  Cancer Res       Date:  2009-07-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.